These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34371444)

  • 1. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
    Hiester A; Fingerhut A; Niegisch G; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Loy V; Wittekind C; Hartmann M; Albers P
    Eur J Cancer; 2021 Sep; 155():64-72. PubMed ID: 34371444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].
    Hartmann M; Siener R; Krege S; Schmelz H; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Albers P;
    Urologe A; 2009 May; 48(5):523-8. PubMed ID: 19183929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.
    McHugh DJ; Funt SA; Silber D; Knezevic A; Patil S; O'Donnell D; Tsai S; Reuter VE; Sheinfeld J; Carver BS; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
    J Clin Oncol; 2020 Apr; 38(12):1332-1337. PubMed ID: 32109195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
    Cullen M; Huddart R; Joffe J; Gardiner D; Maynard L; Hutton P; Mazhar D; Shamash J; Wheater M; White J; Goubar A; Porta N; Witts S; Lewis R; Hall E;
    Eur Urol; 2020 Mar; 77(3):344-351. PubMed ID: 31901440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors.
    Calaway AC; Foster RS; Adra N; Masterson TA; Albany C; Hanna NH; Einhorn LH; Cary C
    J Clin Oncol; 2018 Oct; 36(29):2950-2954. PubMed ID: 30156983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
    Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
    Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Sheinfeld J
    Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
    Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
    Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
    Shamash J; Sarker SJ; Huddart R; Harland S; Joffe JK; Mazhar D; Birtle A; White J; Chowdhury K; Wilson P; Marshall MR; Vinnicombe S
    Ann Oncol; 2017 Jun; 28(6):1333-1338. PubMed ID: 28327896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
    J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.